cd10f4f7-d92b-4152-8595-332686e4605a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- INFLAMMATORY_RESPONSE+0.440
- ANGIOGENESIS+0.420
- TNFA_SIGNALING_VIA_NFKB+0.350
- UV_RESPONSE_DN+0.340
- IL6_JAK_STAT3_SIGNALING+0.290
- KRAS_SIGNALING_UP+0.250
- ALLOGRAFT_REJECTION+0.210
- PROTEIN_SECRETION+0.200
- ANDROGEN_RESPONSE+0.180
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.610
- MYC_TARGETS_V2-0.590
- MYC_TARGETS_V1-0.510
- DNA_REPAIR-0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- FATTY_ACID_METABOLISM-0.410
- ADIPOGENESIS-0.390
- WNT_BETA_CATENIN_SIGNALING-0.370
- PEROXISOME-0.360
- INTERFERON_ALPHA_RESPONSE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 023160e4-1d9a-499c-9bfa-1b3aacf284f2 | — | — | 0.923 |
| 2 | c874c481-cff8-4e2d-99b1-3b5aeaaecb8e | — | — | 0.921 |
| 3 | ad478846-0a75-4081-ac09-37ee5415d9b4 | — | — | 0.902 |
| 4 | 5abd486a-6aed-4dcf-a2a2-2537af6cdd9c | — | — | 0.895 |
| 5 | SRR4195664 | — | — | 0.874 |
| 6 | ec48e2b8-ca0a-40fe-a87b-f0e955466840 | — | — | 0.865 |
| 7 | 1ae8df2d-8c7c-474d-9208-ea63784edc90 | — | — | 0.844 |
| 8 | 07234abb-aa8c-434f-898c-6f7ba28c5850 | — | — | 0.842 |
| 9 | SRR11296851 | — | — | 0.834 |
| 10 | TCGA-D6-6826-01A-11R-1915-07 | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.040 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |